Research Funded by Box Rallies

Featured Research

Professor Micklethwaite and his team are helping the immune system to target and destroy multiple myeloma cells.

Explore Research

Predicting clinical response to breast cancer therapy – the immune signature approach

Preventing people with immune deficiencies from developing cancer

Preventing the outgrowth of cancers that spread to bone

Priming with Belinostat to chemo-sensitise high-risk neuroblastoma

Protein Biosignatures for Predicting Recurrence of Stage II Colorectal Cancer

Rational Targeting of the Hedgehog Pathway to Treat Osteosarcoma

Real-time dose monitoring for patient safety in radiation therapy.

Resolving prostate cancer: Elucidating the epigenetics of tumour microenvironment cells to advance understanding of disease aetiology and improve patient diagnosis

Reversing treatment resistance in ER+ breast cancer

Reversing treatment resistance in melanoma

Selective manipulation of tumour-stroma signalling as a novel precision medicine approach: targeting treatment resistance in pancreatic cancer

Selective targeting of CDK4 to improve breast and prostate cancer treatment

Switching off the spread of triple-negative breast cancer

Targeting aggressive cancers that use the Alternative Lengthening of Telomeres (ALT) mechanism

Targeting Innate Chemoresistance in Lung Adenocarcinoma

Targeting lipid metabolism in pancreatic ductal adenocarcinoma to improve chemotherapy efficacy

Targeting obesity-related factors to enhance liver cancer therapies

Targeting pancreatic cancer (PC) via anti-fibrotic NID2 therapy and Gemcitabine/Abraxane chemotherapy treatment: stratifying PC therapy